First Tracks Biotherapeutics

TRAX · Nasdaq · United States

Share price · TRAX

$44.50+0.62 (+1.41%) 3M

close as of 2026-11-18 · 24h delayed · vol 751K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TRAX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 20 Oct 2026+13.7%
  2. 9 Jul 2026+56.0%
  3. 30 Jun 2026+18.3%

Share of unusual movement by asset

For each asset, the share of TRAX's own-move activity since 21 Apr 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—3%
Sessions with no dated event—97%

No dated announcements about its assets since 21 Apr 2026.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
PD-1 (agonist)Monoclonal antibody
Rheumatoid Arthritis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$24M$156M+ $0 short-term inv.$31M-$17M operating cash flowreport ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$26M$168M+ $0 short-term inv.$33M-$32M operating cash flowreport ↗
2026-Q1—$34M$248M+ $38M short-term inv.$50M-$33M operating cash flowreport ↗
2025-Q3—$33M$110M$42M-$31M operating cash flowreport ↗
2025-Q2—$39M$44M$42M-$39M operating cash flowreport ↗
2025-Q1—$41M$99M$47M-$45M operating cash flowreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$238M+ $73M short-term inv.—-$143M operating cash flowreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$123M+ $262M short-term inv.—-$126M operating cash flowreport ↗
2023-FY——$36M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($66.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-01Lizzul Paul F. · Chief Medical OfficerAward / grant (derivative)42,500——Form 4
2026-11-01STONE BENJAMIN · Chief Business OfficerAward / grant (derivative)42,500——Form 4
2026-11-01Faga Daniel · director, President, CEOAward / grant (derivative)136,000——Form 4
2026-11-01Tamboli Ajim · Chief Financial OfficerAward / grant (derivative)42,500——Form 4
2026-09-15Orwin John A · directorOption exercise1,300——Form 4
2026-09-15Orwin John A · directorOption exercise (derivative)1,300——Form 4
2026-09-02Ware J. Anthony · directorOption exercise39,265$5.74$225KForm 4
2026-09-02Ware J. Anthony · directorOpen-market sale39,265$44.78$1.8MForm 4